Abstract
To investigate the clinical benefits of bevacizumab plus cytotoxic chemotherapy in lung cancer patients with EGFR mutation, we retrospectively assessed clinical data of 159 subjects. The use of the standard chemotherapy with bevacizumab provided better clinical benefit to patients with EGFR mutation than wild-type carriers.
Original language | English |
---|---|
Pages (from-to) | 273-280.e4 |
Journal | Clinical Lung Cancer |
Volume | 21 |
Issue number | 3 |
DOIs | |
Publication status | Published - 05-2020 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research